{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T04:54:10Z","timestamp":1763787250235,"version":"3.45.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02694-2","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T07:09:40Z","timestamp":1755932980000},"page":"2845-2856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic role of the BRAF V600E variant in the preoperative biopsy in differentiated thyroid cancer"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9832-3286","authenticated-orcid":false,"given":"Jos\u00e9 F.","family":"Carrillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5491-8305","authenticated-orcid":false,"given":"Liliana C.","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6887-4722","authenticated-orcid":false,"given":"M\u00f3nica L.","family":"Serrano-Ar\u00e9valo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6711-174X","authenticated-orcid":false,"given":"Wendy B.","family":"P\u00e9rez-B\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5518-5289","authenticated-orcid":false,"given":"Stephanie","family":"Vargas-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5314-2887","authenticated-orcid":false,"given":"Jorge","family":"Aguilar-Frasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5851-6796","authenticated-orcid":false,"given":"Margarita C.","family":"Ram\u00edrez-Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1716-3944","authenticated-orcid":false,"given":"Rafael","family":"V\u00e1zquez-Renter\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6436-3017","authenticated-orcid":false,"given":"Francisco J.","family":"Ochoa-Carrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-0283","authenticated-orcid":false,"given":"Luis F.","family":"O\u00f1ate-Oca\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"2694_CR1","unstructured":"Ferlay J, Ervik M, Lam F et al (2020) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer (available from: IARC. https:\/\/gco.iarc.fr\/today; accessed July 30, 2025)"},{"key":"2694_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jama.2023.26348","volume":"331","author":"L Boucai","year":"2024","unstructured":"Boucai L, Zafereo M, Cabanillas ME (2024) Thyroid cancer: a review. JAMA 331:425\u2013435. https:\/\/doi.org\/10.1001\/jama.2023.26348","journal-title":"JAMA"},{"key":"2694_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1113977","volume":"14","author":"N Uppal","year":"2023","unstructured":"Uppal N, Collins R, James B (2023) Thyroid nodules: global, economic, and personal burdens. Front Endocrinol (Lausanne) 14:1113977. https:\/\/doi.org\/10.3389\/fendo.2023.1113977","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2694_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1089\/thy.2018.0509","volume":"29","author":"T Ibrahimpasic","year":"2019","unstructured":"Ibrahimpasic T, Ghossein R, Shah JP, Ganly I (2019) Poorly differentiated carcinoma of the thyroid gland: current status and future prospects. Thyroid 29:311\u2013321. https:\/\/doi.org\/10.1089\/thy.2018.0509","journal-title":"Thyroid"},{"key":"2694_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010179","volume":"15","author":"J Yuan","year":"2022","unstructured":"Yuan J, Guo Y (2022) Targeted therapy for anaplastic thyroid carcinoma: advances and management. Cancers (Basel) 15:179. https:\/\/doi.org\/10.3390\/cancers15010179","journal-title":"Cancers (Basel)"},{"key":"2694_CR6","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1089\/thy.2019.0812","volume":"30","author":"PH Kim","year":"2020","unstructured":"Kim PH, Suh CH, Baek JH et al (2020) Diagnostic performance of four ultrasound risk stratification systems: a systematic review and meta-analysis. Thyroid 30:1159\u20131168. https:\/\/doi.org\/10.1089\/thy.2019.0812","journal-title":"Thyroid"},{"issue":"6","key":"2694_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11061043","volume":"11","author":"V Fiorentino","year":"2021","unstructured":"Fiorentino V, Dell\u2019 Aquila M, Musarra T et al (2021) The role of cytology in the diagnosis of subcentimeter thyroid lesions. Diagnostics 11(6):1043. https:\/\/doi.org\/10.3390\/diagnostics11061043","journal-title":"Diagnostics"},{"key":"2694_CR8","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/cncy.22139","volume":"127","author":"M Dell\u2019Aquila","year":"2019","unstructured":"Dell\u2019Aquila M, Gravina C, Cocomazzi A et al (2019) A large series of hyalinizing trabecular tumors: cytomorphology and ancillary techniques on fine needle aspiration. Cancer Cytopathol 127:390\u2013398. https:\/\/doi.org\/10.1002\/cncy.22139","journal-title":"Cancer Cytopathol"},{"key":"2694_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/cncy.22224","volume":"128","author":"M Dell\u2019Aquila","year":"2020","unstructured":"Dell\u2019Aquila M, Granitto A, Martini M et al (2020) PD-L1 and thyroid cytology: a possible diagnostic and prognostic marker. Cancer Cytopathol 128:177\u2013189. https:\/\/doi.org\/10.1002\/cncy.22224","journal-title":"Cancer Cytopathol"},{"key":"2694_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159:676\u2013690. https:\/\/doi.org\/10.1016\/j.cell.2014.09.050","journal-title":"Cell"},{"issue":"6","key":"2694_CR11","doi-asserted-by":"publisher","first-page":"e220146","DOI":"10.1530\/ETJ-22-0146","volume":"11","author":"CA Lebbink","year":"2022","unstructured":"Lebbink CA, Links TP, Czarniecka A et al (2022) European thyroid association guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. Eur Thyroid J 11(6):e220146. https:\/\/doi.org\/10.1530\/ETJ-22-0146","journal-title":"Eur Thyroid J"},{"key":"2694_CR12","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s40618-018-0864-6","volume":"41","author":"A Campenni","year":"2018","unstructured":"Campenni A, Ruggeri RM, Siracusa M et al (2018) Combined BRAFV600E analysis and 99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation. J Endocrinol Invest 41:1283\u20131288. https:\/\/doi.org\/10.1007\/s40618-018-0864-6","journal-title":"J Endocrinol Invest"},{"key":"2694_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415626","volume":"23","author":"AS Attia","year":"2022","unstructured":"Attia AS, Hussein M, Issa PP et al (2022) Association of BRAF V600E mutation with the aggressive behavior of papillary thyroid microcarcinoma: a meta-analysis of 33 studies. Int J Mol Sci 23:15626. https:\/\/doi.org\/10.3390\/ijms232415626","journal-title":"Int J Mol Sci"},{"key":"2694_CR14","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1245\/s10434-024-14935-4","volume":"31","author":"HF Lai","year":"2024","unstructured":"Lai HF, Hang JF, Kuo PC et al (2024) BRAF V600E mutation lacks association with poorer clinical prognosis in papillary thyroid carcinoma. Ann Surg Oncol 31:3495\u20133501. https:\/\/doi.org\/10.1245\/s10434-024-14935-4","journal-title":"Ann Surg Oncol"},{"key":"2694_CR15","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/ERC-15-0533","volume":"23","author":"R Liu","year":"2016","unstructured":"Liu R, Xing M (2016) TERT promoter mutations in thyroid cancer. Endocr Relat Cancer 23:R143\u2013155. https:\/\/doi.org\/10.1530\/ERC-15-0533","journal-title":"Endocr Relat Cancer"},{"key":"2694_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9959649","author":"X Wei","year":"2022","unstructured":"Wei X, Wang X, Xiong J et al (2022) Risk and prognostic factors for BRAFV600E mutations in papillary thyroid carcinoma. Biomed Res Int. https:\/\/doi.org\/10.1155\/2022\/9959649","journal-title":"Biomed Res Int"},{"key":"2694_CR17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jasc.2024.04.001","volume":"13","author":"S Tummidi","year":"2024","unstructured":"Tummidi S, Shankaralingappa A, Aravindakshan R (2024) Rapid on-site evaluation and cell blocks: getting the most from the least invasive method in cytopathology. J Am Soc Cytopathol 13:272\u2013284. https:\/\/doi.org\/10.1016\/j.jasc.2024.04.001","journal-title":"J Am Soc Cytopathol"},{"key":"2694_CR18","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/978-3-319-40618-3_73","volume-title":"2017 AJCC cancer staging manual","author":"RM Tuttle","year":"2017","unstructured":"Tuttle RM, Morris LF, Haugen BR, Editors (2017) Thyroid differentiated and anaplastic carcinoma. In: Amin MB, Edge S, Greene F et al (eds) 2017 AJCC cancer staging manual, 8th edn. Springer International Publishing, Chicago, IL, pp 873\u2013890. https:\/\/doi.org\/10.1007\/978-3-319-40618-3_73","edition":"8"},{"key":"2694_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00737","volume":"10","author":"JF Carrillo","year":"2019","unstructured":"Carrillo JF, V\u00e1zquez-Romo R, Ram\u00edrez-Ortega MC et al (2019) Prognostic impact of direct 131I therapy after detection of biochemical recurrence in intermediate or high-risk differentiated thyroid cancer: a retrospective cohort study. Front Endocrinol (Lausanne) 10:737. https:\/\/doi.org\/10.3389\/fendo.2019.00737","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2694_CR20","doi-asserted-by":"crossref","unstructured":"Shidham VB (2021) Cell-blocks and other ancillary studies (including molecular genetic tests and proteomics). Cytojournal 18:4. https:\/\/doi.org\/0.25259\/Cytojournal_3_2021","DOI":"10.25259\/Cytojournal_3_2021"},{"key":"2694_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mcp.2017.06.003","volume":"35","author":"W P\u00e9rez-B\u00e1ez","year":"2017","unstructured":"P\u00e9rez-B\u00e1ez W, Garc\u00eda-Latorre EA, Maldonado-Mart\u00ednez HA et al (2017) Impact of fixation artifacts and threshold selection on high resolution melting analysis for KRAS mutation screening. Mol Cell Probes 35:34\u201343. https:\/\/doi.org\/10.1016\/j.mcp.2017.06.003","journal-title":"Mol Cell Probes"},{"key":"2694_CR22","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJ van Dongen","year":"2003","unstructured":"van Dongen JJ, Langerak AW, Br\u00fcggemann M et al (2003) Design and standardization of PCR primers and protocols for detection of clonal Immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 17:2257\u20132317. https:\/\/doi.org\/10.1038\/sj.leu.2403202","journal-title":"Leukemia"},{"key":"2694_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3892\/etm.2024.12437","volume":"27","author":"Q Liu","year":"2024","unstructured":"Liu Q, Jiang X, Tu W, Liu L et al (2024) Comparative efficiency of differential diagnostic methods for the identification of BRAF V600E gene mutation in papillary thyroid cancer (review). Exp Ther Med 27:149. https:\/\/doi.org\/10.3892\/etm.2024.12437","journal-title":"Exp Ther Med"},{"key":"2694_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153037","volume":"216","author":"W Qi","year":"2020","unstructured":"Qi W, Shi C, Zhang P et al (2020) Effect of BRAF V600E mutation detection of fine- needle aspiration biopsy on diagnosis and treatment guidance of papillary thyroid carcinoma. Pathol Res Pract 216:153037. https:\/\/doi.org\/10.1016\/j.prp.2020.153037","journal-title":"Pathol Res Pract"},{"key":"2694_CR25","doi-asserted-by":"publisher","unstructured":"Katz MH (2011) Multivariable analysis: A practical guide for clinicians and public health researchers. Third edition, Cambridge University Press, Cambridge, UK. https:\/\/doi.org\/10.1017\/CBO9780511974175","DOI":"10.1017\/CBO9780511974175"},{"key":"2694_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1283397","volume":"14","author":"EM Volpi","year":"2023","unstructured":"Volpi EM, Ramirez-Ortega MC, Carrillo JF (2023) Editorial: Recent advances in papillary thyroid carcinoma: diagnosis and predictive factors. Front Endocrinol (Lausanne) 14:1283397. https:\/\/doi.org\/10.3389\/fendo.2023.1283397","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2694_CR27","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1007\/s00268-016-3534-x","volume":"40","author":"S Fraser","year":"2016","unstructured":"Fraser S, Go C, Aniss A et al (2016) BRAF(V600E) mutation is associated with decreased disease-free survival in papillary thyroid cancer. World J Surg 40:1618\u20131624. https:\/\/doi.org\/10.1007\/s00268-016-3534-x","journal-title":"World J Surg"},{"key":"2694_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1590\/2359-3997000000180","volume":"60","author":"AP Cristo","year":"2016","unstructured":"Cristo AP, Goldstein HF, Faccin CS et al (2016) Increasing diagnostic effectiveness of thyroid nodule evaluation by implementation of cell block preparation in routine US-FNA analysis. Arch Endocrinol Metab 60:367\u2013373. https:\/\/doi.org\/10.1590\/2359-3997000000180","journal-title":"Arch Endocrinol Metab"},{"key":"2694_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.20945\/2359-3997000000285","volume":"64","author":"RS Scheffel","year":"2021","unstructured":"Scheffel RS, de Cristo AP, Romitti M et al (2021) The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma. Arch Endocrinol Metab 64:751\u2013757. https:\/\/doi.org\/10.20945\/2359-3997000000285","journal-title":"Arch Endocrinol Metab"},{"key":"2694_CR30","doi-asserted-by":"publisher","first-page":"450","DOI":"10.7150\/ijms.29935","volume":"16","author":"MI Abdullah","year":"2019","unstructured":"Abdullah MI, Junit SM, Ng KL et al (2019) Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. Int J Med Sci 16:450\u2013460. https:\/\/doi.org\/10.7150\/ijms.29935","journal-title":"Int J Med Sci"},{"key":"2694_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"key":"2694_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cancergen.2018.11.002","volume":"230","author":"JI Staubitz","year":"2019","unstructured":"Staubitz JI, Schad A, Springer E et al (2019) Novel rearrangements involving the RET gene in papillary thyroid carcinoma. Cancer Genet 230:13\u201320. https:\/\/doi.org\/10.1016\/j.cancergen.2018.11.002","journal-title":"Cancer Genet"},{"key":"2694_CR33","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317713913","volume":"39","author":"HG Vuong","year":"2017","unstructured":"Vuong HG, Altibi AM, Duong UN et al (2017) Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis. Tumour Biol 39:1010428317713913. https:\/\/doi.org\/10.1177\/1010428317713913","journal-title":"Tumour Biol"},{"key":"2694_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2018.12.003","volume":"108","author":"C Bournaud","year":"2019","unstructured":"Bournaud C, Descotes F, Decaussin-Petrucci M et al (2019) TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma. Eur J Cancer 108:41\u201349. https:\/\/doi.org\/10.1016\/j.ejca.2018.12.003","journal-title":"Eur J Cancer"},{"issue":"6","key":"2694_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13061187","volume":"13","author":"EP Kotanidou","year":"2023","unstructured":"Kotanidou EP, Giza S, Tsinopoulou VR et al (2023) The prognostic significance of BRAF gene analysis in children and adolescents with papillary thyroid carcinoma: a systematic review and meta-analysis. Diagnostics 13(6):1187. https:\/\/doi.org\/10.3390\/diagnostics13061187","journal-title":"Diagnostics"},{"key":"2694_CR36","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/hed.27025","volume":"44","author":"DC Shonka","year":"2022","unstructured":"Shonka DC Jr., Ho A, Chintakuntlawar AV et al (2022) American head and neck society endocrine surgery section and international thyroid oncology group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment. Head Neck 44:1277\u20131300. https:\/\/doi.org\/10.1002\/hed.27025","journal-title":"Head Neck"},{"issue":"5","key":"2694_CR37","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/cen.14316","volume":"94","author":"B Chen","year":"2021","unstructured":"Chen B, Shi Y, Xu Y, Zhang J (2021) The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 94(5):731\u2013742. https:\/\/doi.org\/10.1111\/cen.14316","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2694_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/CCO.0000000000000414","volume":"30","author":"KJ Nicholson","year":"2018","unstructured":"Nicholson KJ, Yip L (2018) An update on the status of molecular testing for the indeterminate thyroid nodule and risk stratification of differentiated thyroid cancer. Curr Opin Oncol 30:8\u201315. https:\/\/doi.org\/10.1097\/CCO.0000000000000414","journal-title":"Curr Opin Oncol"},{"key":"2694_CR39","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/thy.2022.0115","volume":"32","author":"NL Busaidy","year":"2022","unstructured":"Busaidy NL, Konda B, Wei L et al (2022) Dabrafenib versus Dabrafenib\u2009+\u2009Trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial. Thyroid 32:1184\u20131192. https:\/\/doi.org\/10.1089\/thy.2022.0115","journal-title":"Thyroid"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02694-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02694-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02694-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T04:51:56Z","timestamp":1763787116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02694-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2694"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02694-2","relation":{},"ISSN":["1720-8386"],"issn-type":[{"type":"electronic","value":"1720-8386"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"14 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study consent for publication is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The \u201cComit\u00e9 de \u00c9tica en Investigaci\u00f3n\u201d and the \u201cComit\u00e9 de Investigaci\u00f3n\u201d of the INCan reviewed and approved the study protocol.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent to participate"}},{"value":"AI was not employed in the writing process of the present manuscript neither for the data analysis.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Artificial intelligence"}}]}}